Genomics

Dataset Information

0

Pharmacological inhibition of bromodomain and extra-terminal proteins induces NRF-2-mediated inhibition of SARS-CoV-2 replication and is subject to viral antagonism [ATAC-seq]


ABSTRACT: Inhibitors of bromodomain and extra-terminal proteins (iBETs), including JQ-1, have been suggested as potential therapeutics against SARS-CoV-2 infection. However, molecular mechanisms underlying JQ-1-induced antiviral activity and its susceptibility to viral antagonism remain incompletely understood. iBET treatment transiently inhibited infection by SARS-CoV-2 variants and SARS-CoV, but not MERS-CoV. Our functional assays confirmed JQ-1-mediated downregulation of angiotensin-converting enzyme 2 (ACE2) expression and multi-omics analysis uncovered induction of an antiviral NRF-2-mediated cytoprotective response as an additional antiviral component of JQ-1 treatment. Serial passaging of SARS-CoV-2 in the presence of JQ-1 resulted in predominance of ORF6-deficient variants. JQ-1 antiviral activity was transient in human bronchial airway epithelial cells (hBAECs) treated prior to infection and absent when administered therapeutically. We propose that JQ-1 exerts pleiotropic effects that collectively induce a transient antiviral state that is ultimately nullified by an established SARS-CoV-2 infection, raising questions about the clinical suitability of iBETs in the context of COVID-19.

ORGANISM(S): Homo sapiens

PROVIDER: GSE239587 | GEO | 2023/09/18

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-09-18 | GSE239585 | GEO
2023-08-11 | GSE215433 | GEO
2024-02-18 | GSE249500 | GEO
2021-02-19 | ST001709 | MetabolomicsWorkbench
2020-10-20 | GSE159593 | GEO
2024-02-05 | GSE254516 | GEO
2020-12-22 | GSE163624 | GEO
2020-12-22 | GSE163623 | GEO
2022-04-04 | GSE199922 | GEO
| 12454 | ecrin-mdr-crc